This bill amends the Institutional Development Award (IDeA) program statute to (1) formally name the program the 'Institutional Development Award program' or 'IDeA program'; (2) redefine which states qualify as IDeA States by using a median-of-states test based on aggregate NIH grant funding (excluding IDeA awards) calculated on a rolling multi‑year average; and (3) require NIH to produce annual, public reporting — either as part of its federal budget submission or via a maintained data source — describing program strategy, awards, reviewer composition, partnership activity, and five‑year gains in research quality and workforce development.
The measure does not appropriate money or alter award mechanics directly, but it tightens statutory eligibility rules and adds substantive transparency and accountability obligations for NIH. That combination could change which institutions are eligible for IDeA-targeted activities over time and will create new data and compliance work for the agency and recipient institutions while giving Congress, state agencies, and research leaders clearer metrics to assess program performance.
At a Glance
What It Does
The bill updates the PHS Act definition of IDeA States to those at or below the median of state NIH funding (excluding IDeA) using a rolling multi‑year average and mandates annual NIH disclosures about IDeA strategy, awards, reviewer composition, inter‑state partnerships, and five‑year outcome measures. It adds a formal short title for the program.
Who It Affects
The changes primarily affect institutions and investigators located in states that hover near the national median of NIH grant receipts, NIH program and grants-management staff who must compile the new reports, and congressional and state policymakers who use NIH reporting to evaluate federal research capacity programs.
Why It Matters
By codifying an eligibility test and requiring consistent, public reporting on reviewer makeup and partnership activity, the bill shifts the IDeA program toward performance transparency and oversight—potentially influencing reviewer selection, partnership incentives, and how NIH measures success without directly changing funding levels.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The bill touches three discrete things in the IDeA statute. First, it puts the program's short name into the law so references are standardized: 'Institutional Development Award program' or 'IDeA program.' That matters for administrative guidance, notices, and cross‑references inside NIH and among states.
Second, the bill changes how an 'IDeA State' is identified. Rather than leaving the statutory language vague, Congress instructs NIH to treat as eligible those states that are at or below the median of all states in aggregate NIH grant funding, but explicitly excluding funding under the IDeA subsection itself.
The calculation must use a rolling multi‑year average and be determined by the NIH Director. In practice, that creates a moving eligibility line: states' status can change if their non‑IDeA NIH funding grows or falls over the chosen averaging window.Third, the bill creates a package of reporting requirements.
Each year, NIH must either include in its federal budget submission or publish via a maintained public data source: a strategy and objectives statement for the IDeA program; an inventory of prior‑year awards with narrative on integration of IDeA States into major NIH initiatives; the share of IDeA program reviewers from IDeA States; updates on collaborative programs that bridge IDeA and non‑IDeA states; and a five‑year lookback describing gains in research quality and human‑resource development attributable to IDeA activities. Those items are framed as descriptive reporting rather than prescriptive mandates on how NIH runs peer review or awards, but they create explicit metrics that stakeholders will use to judge program performance.Taken together, the changes increase transparency and create incentives for NIH and recipients to show measurable integration of historically underfunded states into broader NIH work.
They also create operational tasks—calculating the rolling median, documenting reviewer affiliation breakdowns, and defining metrics for 'research quality' and 'human resource development'—that NIH and institutions will have to resolve when implementing the law.
The Five Things You Need to Know
The statute explicitly names the program the 'Institutional Development Award program' or the 'IDeA program.', An 'IDeA State' is defined as any state at or below the median of all states in aggregate NIH grant funding, excluding awards under the IDeA subsection, using a rolling multi‑year average set by the NIH Director.
NIH must publish annually (via the federal budget submission or a public data source) a statement of IDeA strategy and objectives and a description of awards made in the prior fiscal year.
The prior‑year awards description must include NIH’s efforts to integrate IDeA States into major NIH initiatives, the percentage of IDeA program reviewers from IDeA States, and updates on large collaborative awards pairing IDeA and non‑IDeA institutions.
NIH must report on gains in academic research quality and biomedical workforce development achieved through the IDeA program over the last five fiscal years.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Short title: 'IDeA Reauthorization Act of 2025'
This is the formal short title; it has no regulatory effect but standardizes references to the legislation in agency documents and appropriations language. Codified short titles matter because they ensure consistency across implementing guidance, Congressional reports, and agency communications.
Statutory naming of the IDeA program
The bill inserts a statutory name for the program. This is administrative housekeeping with downstream effects: grant solicitations, cooperative agreement notices, and internal NIH policies will adopt the exact phrase, reducing ambiguity when combining IDeA activities with other NIH initiatives or when describing program elements to Congress and state partners.
Defines 'IDeA State' using a median-based, rolling funding test
The statute now ties IDeA eligibility to a quantifiable benchmark—the median of all states' NIH grant funding—calculated on a rolling multi‑year average and excluding IDeA subsection funding. Practically, NIH must (a) choose the averaging window and methodology, (b) assemble non‑IDeA NIH award totals by state, and (c) publish determinations. That creates dynamic eligibility: states can move on or off the list as their non‑IDeA NIH funding changes. Excluding IDeA funding prevents circular inflation of eligibility but also means states that rely heavily on IDeA awards could be down‑ranked relative to peers for other NIH funding.
Annual public reporting and Congressional visibility requirements
NIH must submit, along with its budget or via an annually updated public data source, a set of descriptive materials: program strategy and objectives; a summary of prior‑year awards that includes integration efforts, reviewer composition by state, and partnership updates; and a five‑year summary of gains in research quality and workforce development. The statute leaves method and format flexible but creates explicit content items NIH must address, which will influence what data NIH collects and how it documents reviewer pools and partnership outcomes.
This bill is one of many.
Codify tracks hundreds of bills on Science across all five countries.
Explore Science in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Research institutions in currently designated IDeA States — the bill raises transparency about how NIH integrates those institutions into national initiatives, which can help justify state and institutional investment and make collaboration opportunities more visible.
- State science and economic development agencies in IDeA States — the new public data and strategy descriptions provide evidence to support state-level advocacy and planning for workforce and research capacity building.
- Congressional appropriations and oversight staff — standardized, annual reporting gives staff clearer inputs to evaluate program effectiveness and to request targeted follow-up questions or hearings.
Who Bears the Cost
- NIH program and grants-management offices — the agency must design and maintain the rolling median calculation, compile reviewer‑affiliation statistics, track partnership awards, and produce five‑year outcome assessments, all requiring staff time and potentially new data systems.
- Institutional grant administrators in IDeA and near‑median states — to the extent NIH requests data or narrative for the five‑year gains or partnership reporting, institutions will need to prepare documentation and metrics for submission.
- States close to the median threshold — if their non‑IDeA NIH funding rises, they may lose IDeA status and any advantages tied to that designation, creating discontinuities for long‑term local capacity projects.
Key Issues
The Core Tension
The bill pits the desire for clear, comparable accountability and visible integration of underfunded states against the reality that implementing those requirements demands definitional choices and new administrative work by NIH and institutions—and those choices will determine who qualifies as an IDeA State and how success is measured, with no single objectively correct method.
The statute creates useful transparency but leaves key implementation choices to NIH, producing several practical ambiguities. The law requires a 'rolling multi‑year average' and authorizes the NIH Director to determine the calculation, but it does not specify the averaging window, how to treat multi‑component institutions that span states, or the treatment of consortium awards that cross state lines.
Those choices will materially affect which states are designated IDeA and how frequently changes occur.
The reporting obligations are descriptively specific but substantively open. 'Gains in academic research quality' and 'biomedical science human resource development' are meaningful goals but lack statutory definitions or metrics; NIH will need to select indicators (publications, competitive grant success, trainee placements, etc.), which creates risk of inconsistent measures across years or political scrutiny over metric choice. The requirement to report reviewer composition is transparent but does not mandate quotas or alter peer‑review rules; NIH will need to reconcile this disclosure with existing reviewer selection practices and privacy/conflict‑of‑interest protections.
Finally, because the bill does not appropriate funds, NIH must absorb the new administrative workload within existing budgets or seek separate appropriations, which could delay full implementation or limit the quality of reported data.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.